Obesity drug VCT220 tested with common meds in healthy volunteers
NCT ID NCT07056842
First seen Apr 01, 2026 · Last updated May 16, 2026 · Updated 8 times
Summary
This early-stage study looked at how two common drugs (rifampin and itraconazole) change the way the body processes a new experimental medicine called VCT220, which is being developed for obesity. A total of 32 healthy adults took part, with each group receiving either VCT220 plus rifampin or VCT220 plus itraconazole. The main goal was to measure drug levels in the blood and check for side effects, not to treat obesity directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Shandong First Medical University
Jinan, Shandong, 250014, China
Conditions
Explore the condition pages connected to this study.